Abstract: Embodiments of the present disclosure relate to methods, a terminal device, a network device, and computer program products for SCell management in wireless communication. A terminal device receives from a network device configuration information for configuring a triggering mode. The triggering mode is for triggering activation of a secondary cell of the terminal device and a transmission of a temporary reference signal in the secondary cell. Based on the configured triggering mode, the terminal device receives first triggering information on the activation of the secondary cell and second triggering information on the transmission of the temporary reference signal for performing the activation of the secondary cell. In this way, it is possible to reduce the latency of activation/de-activation procedure for SCG and secondary cells.

Abstract: Systems, methods, and circuitries are provided for performing sidelink communication. An example method generates SCI stage 1 and stage 2 for transmitting a transport block (TB) to a user equipment device (UE). The method includes determining the type of sidelink communication for transmitting the TB. An SCI stage 2 format is selected based on the type of sidelink communication. An SCI stage 2 payload is encoded in accordance with the selected SCI stage 2 format. The selected SCI stage 2 format value is encoded in an SCI stage 1 payload. The SCI stage 1 payload and SCI stage 2 payload are transmitted to the UE.

Abstract: Embodiments of the present disclosure relate to methods, devices and computer readable storage media for hybrid automatic repeat request acknowledgement (HARQ-ACK) codebook handling. In example embodiments, a method is provided. The method comprises determining, at a terminal device, respective hybrid automatic repeat request (HARQ) feedback configurations of a plurality of HARQ processes, wherein each HARQ feedback configuration indicates whether HARQ feedback is enabled or disabled for a corresponding HARQ process; and generating a HARQ-ACK codebook for Physical Downlink Shared Channel (PDSCH) based on the HARQ feedback configurations of the plurality of HARQ processes; and transmitting the HARQ-ACK codebook to a network device.

Abstract: Embodiments of the present disclosure relate to uplink transmission with repetitions. According to embodiments of the present disclosure, a user equipment (UE) comprises a transceiver configured to communicate with a network; and a processor communicatively coupled to the transceiver and configured to perform operations. The operations comprise determining first Channel State Information (CSI) and second CSI based on at least one of a previous channel and interference measurement or a latest channel and interference measurement. The operations further comprise transmitting the first CSI via the transceiver to the network with a first beam, the first CSI multiplexed with a first repetition of an uplink transmission with the first beam. The operations further comprise transmitting the second CSI via the transceiver to the network with a second beam, the second CSI multiplexed with a second repetition of the uplink transmission with the second beam.

Abstract: Embodiments of the present disclosure relate to downlink data reception operation. According to embodiments of the present disclosure, a baseband processor of a user equipment (UE) is configured to perform operations comprising receiving Downlink Control Information (DCI) through more than one beams from at least one from at least one TRP; determining a DCI transmission scheme for the received DCI, wherein the DCI transmission scheme is configured by an upper layer signaling, and wherein the DCI transmission scheme is one of a Single Frequency Network (SFN) scheme, a non-SFN scheme, and a hybrid scheme, wherein the DCI is transmitted using both SFN scheme and non-SFH scheme in the hybrid scheme; determining whether the received DCI indicates a Transmission Configuration Indicator (TCI) for PDSCH reception from the at least one TRP or not.

Abstract: A user equipment (UE) is configured to configured to use multiple beams for transmission or reception. The UE receives, from a base station, at least one medium access control (MAC) control element (CE) that indicates multiple activated transmission configuration indicator (TCI) states, receives, from the base station, at least one downlink control information (DCI) indicating a subset of TCI states of the multiple activated TCI states, wherein the MAC CE and the DCI are part of a TCI configuration, and wherein the subset of TCI states corresponds to multiple transmission and reception points (TRPs) of a wireless network, maps the subset of TCI states to the corresponding multiple TRPs based on the TCI configuration and selects a beam used for transmission or reception based on one mapped TCI state of the mapped subset of TCI states.

Abstract: A base station configures a physical uplink control channel (PUCCH) for a user equipment (UE) operating in a frequency band above 52.6 GHz. The base station allocates a predetermined number of resource blocks (RBs) for a physical uplink control channel (PUCCH) transmission, wherein the predetermined number of RBs is greater than one RB, transmits a PUCCH configuration including the predetermined number of RBs to the UE and receives a PUCCH transmission based on the PUCCH configuration and including a data sequence and a DMRS sequence, wherein the PUCCH configuration results in a multiplexing of a plurality of UEs based on a plurality of demodulated reference signal (DMRS) sequences.

Abstract: The present application relates to devices and components including apparatus, systems, and methods to provide adaptive physical downlink control channel (PDCCH) monitoring. In particular, a unified signaling technique for adaptive PDCCH search space monitoring is descried. This signaling can indicate either one or a combination of the switching and skipping. In an example, the signaling includes multiple parts. In a first part, radio resource control (RRC) signaling is sent from the network to the device to configure the device for switching only, skipping only, or switching and skipping. In a second part, first DCI is sent from the network to the device to indicate the particular PDCCH monitoring configuration to use for the PDCCH search space monitoring. Thereafter, network sends second DCI in the relevant PDCCH search space, where this second DCI schedules traffic. The device performs blind decoding to determine the second DCI in order to exchange the traffic.

Abstract: A user equipment is configured to receive a reference signal when secondary cell (SCell is to be activated. The UE receives a secondary cell (SCell) activation indication for activating an SCell, receives a reference signal (RS) triggering indication for triggering an RS prior to an expected SCell activation period, performs measurements on the triggered RS and activates the SCell based on the RS measurements.

Abstract: The present application relates to devices and components including apparatus, systems, and methods to provide SCell activation. In one example, a UE may support carrier aggregation in a high speed mode, such FR1 CA in HST. Serving cells can be particularly configured for the carrier aggregation based on the UE's capability to support carrier aggregation in the high speed mode. Additionally or alternatively, an SCell activation procedure can be performed based on this capability.

Abstract: This disclosure relates to techniques for signaling a quasi-colocation (QCL) update in a wireless communication system. A network or base station may indicate to a UE to change a spatial relationship for transmission/reception. The base station may provide aperiodic reference signals for the UE to use in beam tracking according to the new spatial relationship. Optionally, the base station may also provide aperiodic reference signals for time, frequency, and/or phase tracking. Thus, the network may configure the UE to change to the new spatial relationship and use the aperiodic reference signals to quickly complete initial tracking operations.

Abstract: The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity.

Abstract: The present invention provides an anti-Coxsackie virus oxadiazole compound as represented by formula (I), or the pharmaceutically acceptable salt thereof, a preparation method, a pharmaceutical composition, and use thereof, wherein R is CH3 or CF3; R? and R? are respectively H, alkyl or halogen; A is O or S; n is a number from 1 to 6; X is O, S or NH; Y is alkyl, unsubstituted cycloalkyl, mono-substituted cycloalkyl, disubstituted cycloalkyl, poly-substituted cycloalkyl, unsubstituted aryl, mono-substituted aryl, disubstituted aryl, poly-substituted aryl, unsubstituted 5-6 membered heterocyclyl, mono-substituted 5-6 membered heterocyclyl, disubstituted 5-6 membered heterocyclyl, or poly-substituted 5-6 membered heterocyclyl. Compared to prior art, the oxadiazole compound of the present invention has excellent anti-Coxsackie virus activity, lower toxicity and high safety.

Abstract: Provided are a linezolid intermediate and the preparation method thereof and a method for synthesizing linezolid. The structure of the intermediate is shown as formula F2, wherein the compound is prepared by a condensation reaction of (S)—N-(3-chloro-2-hydroxy-1-propyl) acetamide and the compound shown in formula F4. In the preparation methods of the compound shown in formula F2 and linezolid, the reaction system is mild, side reactions are few and the product yield is high.

Abstract: The present invention relates to a crystalline form of entecavir and its process for preparation, and provides a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of entecavir. Furthermore, the present invention also provides a use of the crystalline form of entecavir in preparation for a medicament for the treatment of hepatitis B viral infections. The present invention is beneficial toe preparations for pharmaceutical formulations and enhancements of its bioavailability.

Abstract: The present invention provides an anti-Coxsackie virus oxadiazole compound as represented by formula (I), or the pharmaceutically acceptable salt thereof, a preparation method, a pharmaceutical composition, and use thereof, wherein R is CH3 or CF3; R? and R? are respectively H, alkyl or halogen; A is O or S; n is a number from 1 to 6; X is O, S or NH; Y is alkyl, unsubstituted cycloalkyl, mono-substituted cycloalkyl, disubstituted cycloalkyl, poly-substituted cycloalkyl, unsubstituted aryl, mono-substituted aryl, disubstituted aryl, poly-substituted aryl, unsubstituted 5-6 membered heterocyclyl, mono-substituted 5-6 membered heterocyclyl, disubstituted 5-6 membered heterocyclyl, or poly-substituted 5-6 membered heterocyclyl. Compared to prior art, the oxadiazole compound of the present invention has excellent anti-Coxsackie virus activity, lower toxicity and high safety.

Abstract: The present invention relates to an intermediate (12) of lycopene of 2,6,10-trimethyl-1,1-dialkoxyl-3,5,9-undecantriene of formula, (12) and its intermediate of 4-methyl-5,5-dialkoxyl-1-pentenyl-1-phosphonic acid dialkyl ester of formula (10), and their preparation methods. The process route is simple, the starting materials are available easily, the cost is low, and it is valuable in industry.

Abstract: The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity.

Abstract: The invention relates to a novel important lycopene intermediate 3,7,11-trimethyl-1,3,6,10-tetraene-dodecyl diethyl phosphonate. A current lycopene intermediate 2,4,6,10-tetra-double bond pentadec-carbon phosphonate is difficult to synthesize. The invention provides a novel intermediate, which has the following synthesis steps of: preparing 2,6,10-trimethyl-3,5,9-undecane triene-1-aldehyde from pseudoionone; preparing 2,6,10-trimethyl-2,5,9-undecane triene-1-aldehyde from the 2,6,10-trimethyl-3,5,9-undecane triene-1-aldehyde; and subjecting the 2,6,10-trimethyl-2,5,9-undecane triene-1-aldehyde and tetraethyl methylenediphosphonate to condensation reaction to obtain target product. The invention can generate novel intermediate from raw material pseudoionone only by four reactions, thus the reactions are easy to control and great industrial value are achieved.

Abstract: The present invention relates to 2,6,10-trimethyl-3,5,9-undecatrienyl-1-aldehyde represented by formula (3), and a method for preparing this intermediate. The process route of the present invention is simple, the starting materials are available easily, and the cost is low.